1. Fluorouracil Error Ends Tragically, But Application of Lessons Learned Will Save. Institute for Safe Medication Practices 2007. Accessed November, 11, 2020
Google Scholar2. Ki, SS, Jeong, JM, Kim, SH, et al. A case of neurotoxicity following 5-fluorouracil-based chemotherapy. Korean J Intern Med Mar. 2002;17(1):73-77.
Google Scholar | Crossref | Medline3. Acharya, G, Cruz Carreras, MT, Rice, TW. 5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer. BMJ Case Rep. 2017;2017.
Google Scholar4. Morrison, GB, Bastian, A, Dela Rosa, T, Diasio, RB, Takimoto, CH. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum. 1997;24(1):83-88.
Google Scholar | Medline5. Takimoto, CH, Lu, ZH, Zhang, R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res Mar. 1996;2(3):477-481.
Google Scholar | Medline6. Akitake, R, Miyamoto, S, Nakamura, F, et al. Early detection of 5-FU-induced acute leukoencephalopathy on diffusion-weighted MRI. Jpn J Clin Oncol Jan. 2011;41(1):121-124.
Google Scholar | Crossref | Medline7. Yeh, KH, Cheng, AL. High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer. 1997;75(3):464-465.
Google Scholar | Crossref | Medline8. Heggie, GD, Sommadossi, JP, Cross, DS, Huster, WJ, Diasio, RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. Apr 15. 1987;47(8):2203-2206.
Google Scholar | Medline | ISI9. Ichikawa, W, Takahashi, T, Suto, K, Sasaki, Y, Hirayama, R. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res Jul. 2006;12(13):3928-3934.
Google Scholar | Crossref | Medline10. Wang, B, Walsh, SJ, Saif, MW. Pancytopenia and severe gastrointestinal toxicities associated with 5-fluorouracil in a patient with thymidylate synthase (TYMS) polymorphism. Cureus. Sep. 2016;8(9):e798.
Google Scholar | Medline11. Danenberg, PV, Gustavsson, B, Johnston, P, et al. Folates as adjuvants to anticancer agents: chemical rationale and mechanism of action. Crit Rev Oncol Hematol. 2016;106:118-131.
Google Scholar | Crossref | Medline12. Ma, WW, Saif, MW, El-Rayes, BF, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017;123(2):345-356.
Google Scholar | Crossref | Medline13. Ison, G, Beaver, JA, McGuinn, WD, et al. FDA approval: uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities following administration of these drugs. Clin Cancer Res. 2016;22(18):4545-4549.
Google Scholar | Crossref | Medline